Health X Platform's Subsidiary Sells Stake to Envision India Fund for ₹500 Cr

Health X Platform's subsidiary, Sastasundar Healthbuddy Limited (SHBL), is set to see a change in its investor base with Envision India Fund acquiring a 4.68% stake for approximately ₹500 crore. Mitsubishi Corporation will exit its shareholding in SHBL upon completion of the deal.

Reader Takeaway: Envision India Fund's entry brings new capital; deal closing hinges on conditions.

What just happened (today’s filing)

Health X Platform Limited announced that its material subsidiary, Sastasundar Healthbuddy Limited (SHBL), has executed a Share Purchase Agreement (SPA).

The agreement is between SHBL, Mitsubishi Corporation (as the seller), and Envision India Fund (as the buyer). Envision India Fund will acquire 10,13,766 equity shares of SHBL.

This stake represents 4.68% of SHBL's total share capital. The transaction is valued at ₹49,99,99,528.86, approximately ₹500.00 crore.

Following the completion of this acquisition, Mitsubishi Corporation will no longer hold any shares in Sastasundar Healthbuddy Limited.

Why this matters

This transaction marks the exit of Mitsubishi Corporation, a long-term investor, from SHBL. Its stake is being acquired by Envision India Fund, suggesting a new chapter for the subsidiary possibly with a different strategic direction or funding focus.

The significant consideration indicates the valuation of this stake within the digital healthcare ecosystem. For Health X Platform Limited, it represents a recalibration of its shareholder structure at the subsidiary level.

The backstory (grounded)

Mitsubishi Corporation had initially invested ₹100 crore in Sastasundar Healthbuddy in August 2019, acquiring a stake of over 10% at that time.

More recently, in November 2025, SHBL conducted a buyback of shares from Mitsubishi Corporation for ₹100 crore. This buyback increased Health X Platform's holding in SHBL from 72.14% to 78.89%.

Health X Platform Limited itself, formerly Sastasundar Ventures Limited, has recently completed a name change to align with its expanded focus on digital health and platform-based operations, effective around February 2026.

What changes now

• Mitsubishi Corporation will no longer be a shareholder in Sastasundar Healthbuddy Limited.
• Envision India Fund will become a significant shareholder in SHBL, bringing in new capital and potentially a new strategic perspective.
• The transaction could pave the way for further growth initiatives or strategic realignments for SHBL under its new investor profile.

Risks to watch

The completion of the share acquisition by Envision India Fund is subject to the satisfaction of agreed terms and conditions stipulated in the Share Purchase Agreement. Any delays or failure to meet these conditions could impact the transaction.

Peer comparison

Sastasundar Healthbuddy Limited operates in the competitive Indian online pharmacy and digital healthcare market. Its peers include major players such as Tata 1mg, PharmEasy, Netmeds, and Apollo Pharmacy. These companies compete on service, product range, pricing, and technology adoption.

Context metrics (time-bound)

N/A

What to track next

• Confirmation of the satisfaction of all terms and conditions outlined in the Share Purchase Agreement.
• The official closing of the share acquisition by Envision India Fund.
• Any future strategic announcements from Health X Platform Limited or Sastasundar Healthbuddy Limited regarding operational changes or expansion plans.